MedTrace Logo

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

NCT05491928 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-09-01

No results posted yet for this study

Summary

The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.

Conditions

Interventions

DRUG

Tempol

Tempol will be given as an adjunct to chemotherapy.

Sponsors & Collaborators

  • Matrix Biomed, Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05491928 on ClinicalTrials.gov